Literature DB >> 1353684

Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs.

J Bongers1, T Lambros, M Ahmad, E P Heimer.   

Abstract

The kinetics and selectivity of proteolysis of synthetic human growth hormone-releasing factor and analogs by purified human placental dipeptidyl peptidase IV (DPP IV) were studied by HPLC. The initial rates of Ala2-Asp3 cleavage (pH 7.8, 37 degrees C, So = 0.15 mM) were all approx. 5 mumol min-1 mg-1 for the parent hormone, GRF(1-44)-NH2, and the fragments, GRF(1-29)-NH2 and GRF(1-20)-NH2. Lower activities observed for GRF(1-11)-OH, GRF(1-3)-OH, and cyclic lactam analogs indicate S1'-Sn' binding. Assays of [Trp6]-GRF(1-29)-NH2 versus [D-Trp6]-GFR(1-29)-NH2 indicate an S4' binding cavity. Peptides with D-configuration at P2, P1 or P1' and desNH2Tyr1 and N-MeTyr1 analogs of GRF were not cleaved. Catalytic parameters for the P1-substituted analogs [X2,Ala15]-GRF(1-29)-NH2 were found to vary with X as follows, Km: Abu less than Ala less than Pro less than Val less than Ser less than Gly much less than Leu; kcat: Pro greater than Ala greater than Abu greater than Ser greater than Gly much greater than Leu greater than Val; kcat/Km: Abu greater than Pro greater than Ala much greater than Ser greater than Gly = Val much greater than Leu. Km is at a minimum and kcat/Km at a maximum, for a hydrophobic P1 side-chain of about 0.25 nm in length, i.e., the ethyl side-chain of alpha-aminobutyric acid (Abu) is very close to optimal. These results further define the S1 selectivity of DPP IV and may be useful in the design of DPP IV resistant GRF analogs that can be produced by recombinant DNA methods and the design of DPP IV inhibitors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1353684     DOI: 10.1016/0167-4838(92)90317-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  16 in total

Review 1.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

2.  Degradation of Incretins and Modulation of Blood Glucose Levels by Periodontopathic Bacterial Dipeptidyl Peptidase 4.

Authors:  Yuko Ohara-Nemoto; Manami Nakasato; Yu Shimoyama; Tomomi T Baba; Takeshi Kobayakawa; Toshio Ono; Takashi Yaegashi; Shigenobu Kimura; Takayuki K Nemoto
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

3.  Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy.

Authors:  Rosa Barreira da Silva; Melissa E Laird; Nader Yatim; Laurence Fiette; Molly A Ingersoll; Matthew L Albert
Journal:  Nat Immunol       Date:  2015-06-15       Impact factor: 25.606

4.  CD26 protease inhibition improves functional response of unfractionated cord blood, bone marrow, and mobilized peripheral blood cells to CXCL12/SDF-1.

Authors:  Kent W Christopherson; Robin R Frank; Sucheta Jagan; Laura A Paganessi; Stephanie A Gregory; Henry C Fung
Journal:  Exp Hematol       Date:  2012-07-27       Impact factor: 3.084

5.  Loss of CD26 protease activity in recipient mice during hematopoietic stem cell transplantation results in improved transplant efficiency.

Authors:  Eunsun Yoo; Laura A Paganessi; Wasfia A Alikhan; Elizabeth A Paganessi; Frank Hughes; Henry C Fung; Elizabeth Rich; Chu Myong Seong; Kent W Christopherson
Journal:  Transfusion       Date:  2012-08-06       Impact factor: 3.157

6.  Proteome-wide reactivity profiling identifies diverse carbamate chemotypes tuned for serine hydrolase inhibition.

Authors:  Jae Won Chang; Armand B Cognetta; Micah J Niphakis; Benjamin F Cravatt
Journal:  ACS Chem Biol       Date:  2013-05-23       Impact factor: 5.100

7.  Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene.

Authors:  C A Abbott; E Baker; G R Sutherland; G W McCaughan
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

8.  Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation.

Authors:  Kathleen Aertgeerts; Sheng Ye; Mike G Tennant; Michelle L Kraus; Joe Rogers; Bi-Ching Sang; Robert J Skene; David R Webb; G Sridhar Prasad
Journal:  Protein Sci       Date:  2004-01-10       Impact factor: 6.725

9.  Mass spectrometry-assisted confirmation of the inability of dipeptidyl peptidase-4 to cleave goldfish peptide YY(1-36) and the lack of anorexigenic effects of peptide YY(3-36) in goldfish (Carassius auratus).

Authors:  R Gonzalez; S Unniappan
Journal:  Fish Physiol Biochem       Date:  2015-12-16       Impact factor: 2.794

10.  Clinical and oncologic implications in epigenetic down-regulation of CD26/dipeptidyl peptidase IV in adult T-cell leukemia cells.

Authors:  Tomohiro Tsuji; Kazuyuki Sugahara; Kazuto Tsuruda; Akiko Uemura; Hitomi Harasawa; Hiroo Hasegawa; Yukio Hamaguchi; Masao Tomonaga; Yasuaki Yamada; Shimeru Kamihira
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.